If you were injured by prescription testosterone such as Androgel® you are not alone. To date thousands of lawsuits have been filed against the manufacturers of prescription testosterone over injuries that may have been caused by testosterone. The most common injuries associated with supplemental prescription testosterone use are heart attack, stroke, pulmonary embolism or deep vein thrombosis. Some testosterone products are: Androgel® Androderm® Axiron® Testim® Depo Testosterone® Recent medical studies show that supplemental testosterone therapy leads to an increased risk of cardiovascular injury by 30%.
Many patients in need of a blood thinning medication thought a new drug Xarelto® was the answer to their problem. Xarelto was marketed as better than warfarin, an older medication, and it did not require patients to undergo frequent blood tests. Unfortunately, however, the use of Xarelto came with a heavy price – uncontrolled bleeding and no antidote to stop the bleeding. Individuals using Xarelto have experienced internal or gastrointestinal bleeding, brain hemorrhages, hemorrhagic strokes and death from bleeding that would not stop. According to Quarter Watch, Xarelto accounted for 10,674 serious adverse event reports in calendar year 2015 with 1,121 deaths and 4,508 injuries requiring hospitalization. Xarelto is manufactured by Bayer AG and in calendar year 2014, Xarelto accounted for sales totaling 3.5 billion euros. For calendar year 2015, Xarelto sales increased 34% from calendar year 2014.
The story of the harm to users of Proton Pump Inhibitors (PPIs) has been hidden in medical journals for decades. It remained a secret until an article gained much needed attention in April 2016. First, the drugs at issue include both prescription and over-the-counter medicine such as Nexium®, Prevacid®, Prilosec®, Protonix® or Aciphex®. PPIs are used to treat heart burn, acid reflux and ulcers. The article titled, “PPIs and Kidney Injury: Longer Use Tied to Higher Risk”, Medscape, April 14, 2016. For the study researchers analyzed data from the Veterans Administration and identified 173,321 new users of PPI and 20,270 new users of H2 blocker. H2 blockers are drugs such as Tagemet®, Pepcid® or Zantax®. Both classes of drugs are used from the same medical issue. The study revealed that over the course of 5 years that patients who were prescribed PPI were 22% more likely to have a drop in their glomerular filtration rate than users of H2 blockers. In addition, users of PPI, such as Nexium, Prevacid or Prilosec were 28% more likely to develop chronic kidney disease than users of H2 blockers.
In 2006 the IARC (International Agency for Research on Cancer) classified genital talc use as a possible carcinogen to humans. Now a new study demonstrates that women who use talcum powder are at a greater risk for developing ovarian cancer than non-users. The study reveals that the risk is 33% higher for users of regular talc as opposed to non-users. Talc was originally implicated as a possible ovarian cancer risk because of its chemical similarity to asbestos which is known to cause ovarian cancer in certain occupational settings. In Talc lawsuits, filed against Johnson & Johnson, it is alleged that talc fiber travel through the genital track and gain access to the ovaries. It is alleged that Johnson & Johnson have known for years of the heightened risk of ovarian cancer to women who use talcum powder, but that Johnson & Johnson did not warn users about the risk.
The new wonder drug Invokana® was controversial from the inception. The drug was approved in March 2013 by a vote of 10 to 5 of the FDA Endocrinologic and Metabolic Drugs Advisory Committee with panel members expressing concern over the risk of kidney damage, heart attack and stroke associated with the drug. In addition, some members of the panel were concerned about the “small volume of data” to support use of the product. Invokana® is manufactured by Janssen Pharmaceuticals a subsidiary of Johnson & Johnson.
The fluoroquinolones, antibiotics, is a long story of what can go wrong with what is perceived as a safe product. Common fluoroquinolones are: Avelox®, Cipro®, and Levaquin®. Fluoroquinolones (FLQ) are among the most prescribed antibiotics so adverse events can have significant public health implications for many. The early controversy over FLQ involved tendonitis and Achilles tendon rupture. In the early 90’s medical research focused on tendon rupture. Researchers speculated that FLQ’s affected collagen in some way because tendons are composed collagen fibers. Collagen is a unique structure that is stronger than steel. It is found throughout the body in cartilage, blood vessels, the cornea, muscles and the gastrointestinal tract. There are several types of collagen. Type I and type III collagen comprise the majority of collagen in the Achilles tendon. Approximately 90% of collagen in normal tendons is Type I and 10% is Type III. Over the years medical studies have coalesce around the proposition that FLQ interfered with collagen fibrils found in Type I collagen. Medical studies indicate discuss FLQ’s such as Cipro exert a negative effect on tendon structure or its healing process through the mechanism by up-regulating gelantinase (MMP-2) expression. According to the Tsai study, type I collagen is degraded after treatment with ciprofloxacin. Over the years fluoroquinolone tendon ruptures are a recognized complication of this class of drugs.
INVOKANA® BLACK BOX WARNING LEG, TOE & FOOT AMPUTATIONS The Food & Drug Administration (FDA) is requiring a black box warning to appear for Invokana® and Invokamet® alerting users and…
Invokana® Lawsuit News! A Invokana kidney injury case can proceed according to a federal judge. No preemption exists according to Judge Martin Feldman. The case concerns the plaintiff developing acute…